Advertisement

Whole-Cell Vaccine Preparation: Options and Perspectives

Protocol
First Online:
  • 1.4k Downloads
Part of the Methods in Molecular Biology book series (MIMB, volume 2183)

Abstract

Vaccines are biological preparations to elicit a specific immune response in individuals against the targetted microorganisms. The use of vaccines has caused the near eradication of many critical diseases and has had an everlasting impact on public health at a relatively low cost. Most of the vaccines developed today are based on techniques which were developed a long time ago. In the beginning, vaccines were prepared from tissue fluids obtained from infected animals or people, but at present, the scenario has changed with the development of vaccines from live or killed whole microorganisms and toxins or using genetic engineering approaches. Considerable efforts have been made in vaccine development, but there are still many diseases that need attention, and new technologies are being developed in vaccinology to combat them. In this chapter, we discuss different approaches for vaccine development, including the properties and preparation of whole-cell vaccines.

Key words

Vaccines Diseases Inactivation Attenuation Conjugated vaccines Whole-cell vaccines 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors duly acknowledge M.D. University, Rohtak, India, for providing infrastructural facilities. Sunita acknowledges the support as University Research Scholarship by M.D. University, Rohtak, India. PS acknowledges the infrastructural support from Department of Science and Technology, Govt. of India, New Delhi, through FIST grant (Grant No. 1196 SR/FST/LS-I/2017/4).

References

  1. 1.
    WHO, Vaccines. https://www.who.int/topics/vaccines/en/. Accessed 31 May 2019
  2. 2.
    Bragazzi NL, Gianfredi V, Villarini M, Rosselli R, Nasr A, Hussein A, Martini M, Behzadifar M (2018) Vaccines meet big data: state-of-the-art and future prospects. From the Classical 3Is (“Isolate-Inactivate-Inject”) Vaccinology 1.0 to Vaccinology 3.0, vaccinomics, and beyond: a historical overview. Front Public Health 6:62.  https://doi.org/10.3389/fpubh.2018.00062CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lahariya C (2014) A brief history of vaccines & vaccination in India. Indian J Med Res 139(4):491–511PubMedPubMedCentralGoogle Scholar
  4. 4.
    McCullers JA, Dunn JD (2008) Advances in vaccine technology and their impact on managed care. P T 33(1):35–41PubMedPubMedCentralGoogle Scholar
  5. 5.
    WHO, Children: reducing mortality, 19 September 2018. https://www.who.int/en/news-room/fact-sheets/detail/children-reducing-mortality. Accessed 07 June 2019
  6. 6.
    Gizurarson S (1996) Optimal delivery of vaccines: clinical pharmacokinetic considerations. Clin Pharmacokinet 30(1):1–15PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Jódar L, Feavers IM, Salisbury D, Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet 359(9316):1499–1508PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Byrne MP, Smith LA (2000) Development of vaccines for prevention of botulism. Biochimie 82(9–10):955–966PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Smith LA (1998) Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36(11):1539–1548PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT (2008) Subunit vaccine against the seven serotypes of botulism. Infect Immun 76(3):1314–1318PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Levine MM (2010) Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 8(1):129PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Ryan ET, Calderwood SB (2000) Cholera vaccines. Clin Infect Dis 31(2):561–565PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Lobeck K, Drevet P, Léonetti M, Fromen-Romano C, Ducancel F, Lajeunesse E, Lemaire C, Ménez A (1998) Towards a recombinant vaccine against diphtheria toxin. Infect Immun 66(2):418–423PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Rappuoli R, Malito E (2014) History of Diphtheria vaccine development. In: Burkovski A (ed) Corynebacterium diphtheriae and related toxigenic species. Springer, DordrechtGoogle Scholar
  15. 15.
    Titball RW, Williamson ED (2004) Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 4(6):965–973PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Morris SR (2007) Development of a recombinant vaccine against aerosolized plague. Vaccine 25(16):3115–3117PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Sato Y, Sato H (1999) Development of acellular pertussis vaccines. Biologicals 27(2):61–69PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Granström M (2011) The history of pertussis vaccination: from whole-cell to subunit vaccines. In: Plotkin S (ed) History of vaccine development. Springer, New YorkGoogle Scholar
  19. 19.
    Sutter RW, Prevots DR, Cochi SL (2000) Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatr Clin N Am 47(2):287–308CrossRefGoogle Scholar
  20. 20.
    Baicus A (2012) History of polio vaccination. World J Virol 1(4):108–114.  https://doi.org/10.5501/wjv.v1.i4.108CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Liu Y, Wang J, Liu S, Du J, Wang L, Gu W, Xu Y, Zuo S, Xu E, An Z (2017) Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014. Vaccine 35(9):1281–1286.  https://doi.org/10.1016/j.vaccine.2017.01.034CrossRefPubMedGoogle Scholar
  22. 22.
    Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20(25–26):3155–3164PubMedCrossRefGoogle Scholar
  23. 23.
    Dubey KK, Luke GA, Knox C, Kumar P, Pletschke BI, Singh PK, Shukla P (2018) Vaccine and antibody production in plants: developments and computational tools. Brief Funct Genomics 17(5):295–307.  https://doi.org/10.1093/bfgp/ely020CrossRefPubMedGoogle Scholar
  24. 24.
    Yang DK, Kim HH, Lee SH, Jeong WH, Tark D, Cho IS (2017) A genetically modified rabies vaccine (ERAGS) induces protective immunity in dogs and cattle. Clin Exp Vaccine Res 6(2):128–134.  https://doi.org/10.7774/cevr.2017.6.2.128CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL (2001) Developing new smallpox vaccines. Emerg Infect Dis 7(6):920PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Parrino J, Graham BS (2006) Smallpox vaccines: past, present, and future. J Allergy Clin Immunol 118(6):1320–1326PubMedCrossRefGoogle Scholar
  27. 27.
    Moss B (2011) Smallpox vaccines: targets of protective immunity. Immunol Rev 239(1):8–26.  https://doi.org/10.1111/j.1600-065X.2010.00975.xCrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Figueiredo D, Turcotte C, Frankel G, Li Y, Dolly O, Wilkin G, Marriott D, Fairweather N, Dougan G (1995) Characterization of recombinant tetanus toxin derivatives suitable for vaccine development. Infect Immun 63(8):3218–3221PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Verma R, Khanna P (2012) Tetanus toxoid vaccine: elimination of neonatal tetanus in selected states of India. Hum Vaccin Immunother 8(10):1439–1442.  https://doi.org/10.4161/hv.21145CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A, Favre D, Dietrich G (2006) Vaccines against typhoid fever. Vaccine 24(18):3804–3811PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Szu SC (2013) Development of Vi conjugate–a new generation of typhoid vaccine. Expert Rev Vaccines 12(11):1273–1286PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Jackson BR, Iqbal S, Mahon B, Centers for Disease Control and Prevention (CDC) (2015) Updated recommendations for the use of typhoid vaccine—advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 64(11):305–308PubMedPubMedCentralGoogle Scholar
  33. 33.
    Hilleman MR (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. J Hum Virol 3(2):63–76PubMedPubMedCentralGoogle Scholar
  34. 34.
    Plotkin SA, Plotkin SL (2011) The development of vaccines: how the past led to the future. Nat Rev Microbiol 9(12):889–893.  https://doi.org/10.1038/nrmicro2668CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Plotkin SA, Gilbert PB (2012) Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54(11):1615–1617PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Plotkin S (2014) History of vaccination. Proc Natl Acad Sci U S A 111(34):12283–12287.  https://doi.org/10.1073/pnas.1400472111CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Stauffer F, El-Bacha T, Da Poian AT (2006) Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov 1(3):291–296PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Scott C (2004) Classifying vaccines: from cowpox to the cutting edge. BioProcess Int 2:14–23Google Scholar
  39. 39.
    Plotkin SA (2009) Vaccines: the fourth century. Clin Vaccine Immunol 16(12):1709–1719.  https://doi.org/10.1128/CVI.00290-09CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Vartak A, Sucheck SJ (2016) Recent advances in subunit vaccine carriers. Vaccines (Basel) 4(2):12.  https://doi.org/10.3390/vaccines4020012CrossRefGoogle Scholar
  41. 41.
    The history of vaccines; Different types of vaccines. https://www.historyofvaccines.org/content/articles/different-types-vaccines. Accessed 09 June 2019
  42. 42.
    Minor PD (2015) Live attenuated vaccines: historical successes and current challenges. Virology 479–480:379–392PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Baxby D (2003) Smallpox vaccination techniques. 2. Accessories and aftercare. Vaccine 21(13–14):1382–1390PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Luca S, Mihaescu T (2013) History of BCG vaccine. Maedica (Buchar) 8(1):53–58Google Scholar
  45. 45.
    Collins ND, Barrett AD (2017) Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day. Curr Infect Dis Rep 19(3):14.  https://doi.org/10.1007/s11908-017-0566-9CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Pliaka V, Kyriakopoulou Z, Markoulatos P (2012) Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 11(5):609–628PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, Ryan J (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327(7):453–457PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Wood JM, Robertson JS (2004) From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2(10):842PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P (2010) Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28(22):3827–3840PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Vijaykrishna D, Mukerji R, Smith GJ (2015) RNA virus reassortment: an evolutionary mechanism for host jumps and immune evasion. PLoS Pathog 11(7):e1004902.  https://doi.org/10.1371/journal.ppat.1004902CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Clark HF, Offit PA, Plotkin SA, Heaton PM (2006) The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr Infect Dis J 25(7):577–583PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Tan LK, Carlone GM, Borrow R (2010) Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 362(16):1511–1520PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Ni Y, Springer MJ, Guo J, Finger-Baker I, Wilson JP, Cobb RR, Turner D, Tizard I (2017) Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine 35(51):7121–7126.  https://doi.org/10.1016/j.vaccine.2017.10.081CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR (1993) Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 270(15):1826–1831PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13(2):302–317PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Lee CJ, Lee LH, Koizumi K (2002) Polysaccharide vaccines for prevention of encapsulated bacterial infections: part 1. Inf Med 19(3):127–133Google Scholar
  57. 57.
    AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H (1995) Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Mol Biol Rev 59(4):591–603Google Scholar
  58. 58.
    Dekleva ML (2002) Vaccine technology. In: Flickinger MC, Drew SW (eds) Encyclopedia of bioprocess technology. Wiley, New York.  https://doi.org/10.1002/0471250589.ebt215CrossRefGoogle Scholar
  59. 59.
    Kelly DF, Moxon ER, Pollard AJ (2004) Haemophilus influenzae type b conjugate vaccines. Immunology 113(2):163–174.  https://doi.org/10.1111/j.1365-2567.2004.01971.xCrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Maiden MC (2013) The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? Philos Trans R Soc Lond Ser B Biol Sci 368(1623):20120147.  https://doi.org/10.1098/rstb.2012.0147CrossRefGoogle Scholar
  61. 61.
    Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32(3):155–172PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Marciani DJ (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8(20):934–943PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Alving CR, Peachman KK, Rao M, Reed SG (2012) Adjuvants for human vaccines. Curr Opin Immunol 24(3):310–315PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Mulard L (2007) Carbohydrates and vaccines: from purified polysaccharides to semi-synthetic glycoconjugate vaccines. Ann Pharm Fr 65(1):14–32PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Colombo C, Pitirollo O, Lay L (2018) Recent advances in the synthesis of glycoconjugates for vaccine development. Molecules 23(7):1712.  https://doi.org/10.3390/molecules23071712CrossRefPubMedCentralGoogle Scholar
  66. 66.
    Gupta SK, Shukla P (2018) Glycosylation control technologies for recombinant therapeutic proteins. Appl Microbiol Biotechnol 102(24):10457–10468PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Vartak A, Sucheck S (2016) Recent advances in subunit vaccine carriers. Vaccine 4(2):12CrossRefGoogle Scholar
  68. 68.
    Zhang N, Zheng BJ, Lu L, Zhou Y, Jiang S, Du L (2015) Advancements in the development of subunit influenza vaccines. Microbes Infect 17(2):123–134.  https://doi.org/10.1016/j.micinf.2014.12.006CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Astray RM, Jorge SA, Pereira CA (2017) Rabies vaccine development by expression of recombinant viral glycoprotein. Arch Virol 162(2):323–332.  https://doi.org/10.1007/s00705-016-3128-9CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    MacLennan CA, Martin LB, Micoli F (2014) Vaccines against invasive Salmonella disease: current status and future directions. Hum Vaccin Immunother 10(6):1478–1493.  https://doi.org/10.4161/hv.29054CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Baliban SM, Yang M, Ramachandran G, Curtis B, Shridhar S, Laufer RS et al (2017) Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa. PLoS Negl Trop Dis 11(4):e0005493.  https://doi.org/10.1371/journal.pntd.0005493CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Micoli F, Romano MR, Tontini M, Cappelletti E, Gavini M, Proietti D, Rondini S, Swennen E, Santini L, Filippini S, Balocchi C (2013) Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. PNAS 110(47):19077–19082PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Dertzbaugh MT (1998) Genetically engineered vaccines: an overview. Plasmid 39(2):100–113PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Gupta SK, Shukla P (2017) Gene editing for cell engineering: trends and applications. Crit Rev Biotechnol 37(5):672–684.  https://doi.org/10.1080/07388551.2016.1214557CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Dangi AK, Sinha R, Dwivedi S, Gupta SK, Shukla P (2018) Cell line techniques and gene editing tools for antibody production: a review. Front Pharmacol 9:630.  https://doi.org/10.3389/fphar.2018.00630CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Nascimento IP, Leite LC (2012) Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 45(12):1102–1111PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Buck CB, Day PM, Trus BL (2013) The papillomavirus major capsid protein L1. Virology 445(1–2):169–174PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP (2007) Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine 25(51):8574–8584PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Gustavsson M, Do TH, Lüthje P, Tran NT, Brauner A, Samuelson P, Truong NH, Larsson G (2015) Improved cell surface display of Salmonella enterica serovar Enteritidis antigens in Escherichia coli. Microb Cell Factories 14:47.  https://doi.org/10.1186/s12934-015-0227-3CrossRefGoogle Scholar
  80. 80.
    Peng W, Liu S, Meng J, Huang J, Huang J, Tang D, Dai Y (2019) Profiling the TRB and IGH repertoire of patients with H5N6 Avian Influenza Virus Infection by high-throughput sequencing. Sci Rep 9(1):7429PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Auniņš JG (2009) Viral vaccine production in cell culture. In: Flickinger MC (ed) Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. Wiley, New York, pp 1–35Google Scholar
  82. 82.
    Karch CP, Burkhard P (2016) Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol 120:1–14PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    WHO Expert Committee on Biological Standardization. WHO technical report series, no. 941—Fifty-sixth report, Annex 6: recommendations for whole-cell pertussis vaccine, 301–33. WHO HQ, Geneva, 2007. http://apps.who.int/medicinedocs/en/cl/CL7.13/clmd,50.html
  84. 84.
    Chen Z, He Q (2017) Immune persistence after pertussis vaccination. Hum Vaccin Immunother 13(4):744–756PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Xing D, Markey K, Das RG, Feavers I (2014) Whole-cell pertussis vaccine potency assays: the Kendrick test and alternative assays. Expert Rev Vaccines 13(10):1175–1182.  https://doi.org/10.1586/14760584.2014.939636CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Corbel MJ, Xing DK (2004) Toxicity and potency evaluation of pertussis vaccines. Expert Rev Vaccines 3(1):89–101PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Holmgren J, Levine MM (2015) Vaccines against bacterial enteric infections. In: Mestecky J, Strober W, Russel MW, Kelsall BL, Cheroutre H, Lambrecht BN (eds) Mucosal immunology, vol 1, 4th edn. Academic, New York, pp 1047–1082.  https://doi.org/10.1016/C2010-1-65194-2CrossRefGoogle Scholar
  88. 88.
    Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J (1995) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334(6):349–356CrossRefGoogle Scholar
  89. 89.
    Cabral MP, García P, Beceiro A, Rumbo C, Pérez A, Moscoso M, Bou G (2017) Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy. Nat Commun 8:15480PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Serruto D, Serino L, Masignani V, Pizza M (2009) Genome-based approaches to develop vaccines against bacterial pathogens. Vaccine 27(25–26):3245–3250PubMedCrossRefGoogle Scholar
  91. 91.
    Essig A, Longbottom D (2015) Chlamydia abortus: new aspects of infectious abortion in sheep and potential risk for pregnant women. Curr Clin Microbiol Rep 2(1):22–34CrossRefGoogle Scholar
  92. 92.
    Phillips S, Quigley BL, Timms P (2019) Seventy years of Chlamydia vaccine research–limitations of the past and directions for the future. Front Microbiol 10:70.  https://doi.org/10.3389/fmicb.2019.00070CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Sharma A, Rajan G, Kharb R, Biswas S (2016) Genome wide analysis of Chlamydia pneumoniae for candidate vaccine development. Curr Comput Aided Drug Des 12(3):206–215PubMedCrossRefGoogle Scholar
  94. 94.
    Bi Q, Ferreras E, Pezzoli L et al (2017) Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis 17(10):1080–1088PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Chowdhury SR, Sarkar A, Kumar RP, Kumar V, Saxena D, Barman BD (2018) Periodontal vaccine–a review. J Adv Med Dent Scie Res 6(3):4–9Google Scholar
  96. 96.
    de Castro JT, Miyaji EN, Soares-Schanoski A, Debrie AS, Bezerra MF, Akamatsu MA, de Oliveira MS (2018) Whole cell pertussis vaccine expressing the Pneumococcal Surface protein A as an approach for a double vaccine. Int J Infect Dis 73:356CrossRefGoogle Scholar
  97. 97.
    Soema PC, Kompier R, Amorij JP, Kersten GF (2015) Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 94:251–263PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Kraan H, ten Have R, van der Maas L, Kersten G, Amorij JP (2016) Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine. Vaccine 34(38):4572–4578PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Zhang W, Cheng N, Wang Y, Zheng X, Zhao Y, Wang H, Yang S (2019) Adjuvant activity of PCP-II, a polysaccharide from Poria cocos, on a whole killed rabies vaccine. Virus Res 270:197638.  https://doi.org/10.1016/j.virusres.2019.06.001CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Domenech de Cellès M, Magpantay FM, King AA, Rohani P (2016) The pertussis enigma: reconciling epidemiology, immunology and evolution. Proc R Soc Lond B Biol Sci 283(1822):20152309Google Scholar
  101. 101.
    Mattia G, Puglisi R, Ascione B, Malorni W, Carè A, Matarrese P (2018) Cell death-based treatments of melanoma: conventional treatments and new therapeutic strategies. Cell Death Dis 9(2):112.  https://doi.org/10.1038/s41419-017-0059-7CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Yarchoan M, Johnson BA III, Lutz ER, Laheru DA, Jaffee EM (2017) Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17(4):209PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Keenan BP, Jaffee EM (2012) Whole cell vaccines—past progress and future strategies. Semin Oncol 39(3):276–286.  https://doi.org/10.1053/j.seminoncol.2012.02.007CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Barouch DH, Letvin NL, Seder RA (2004) The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 202(1):266–274PubMedCrossRefGoogle Scholar
  105. 105.
    Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Svane IM (2017) Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study. Cytotherapy 19(4):500–513PubMedCrossRefGoogle Scholar
  106. 106.
    World Health Organization fact sheet Cholera. https://www.who.int/news-room/fact-sheets/detail/cholera. Accessed 28 July 2019
  107. 107.
    Gupta SS, Bharati K, Sur D, Khera A, Ganguly NK, Nair GB (2016) Why is the oral cholera vaccine not considered an option for prevention of cholera in India? Analysis of possible reasons. Indian J Med Res 143(5):545–551.  https://doi.org/10.4103/0971-5916.187102CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Ciglenecki I, Bichet M, Tena J, Mondesir E (2013) Cholera in pregnancy: outcomes from a specialized cholera treatment unit for pregnant women in Leogane. Haiti PLoS Negl Trop Dis 7:e2368PubMedCrossRefGoogle Scholar
  109. 109.
    Grout L, Martinez-Pino I, Ciglenecki I, Keita S, Traore B, Delamou D, Serafini M (2015) Pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine in Guinea: a retrospective cohort study. PLoS Negl Trop Dis 9(12):e0004274PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Khan AI, Ali M, Lynch J, Kabir A, Excler JL, Khan MA, Islam MT, Akter A, Chowdhury F, Saha A, Khan IA, Desai SN, Kim DR, Saha NC, Singh AP, Clemens JD, Qadri F (2019) Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial. BMC Infect Dis 19(1):422.  https://doi.org/10.1186/s12879-019-4006-3CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Khan AI, Chowdhury F, Leung DT, Larocque RC, Harris JB, Ryan ET, Calderwood SB, Qadri F (2015) Cholera in pregnancy: clinical and immunological aspects. Int J Infect Dis 39:20–24.  https://doi.org/10.1016/j.ijid.2015.08.006CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE (2008) Malaria: progress, perils, and prospects for eradication. J Clin Invest 118(4):1266–1276PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Ellis RD, Sagara I, Doumbo O, Wu Y (2010) Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccin 6(8):627–634PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Richards JS, Beeson JG (2009) The future for blood-stage vaccines against malaria. Immunol Cell Biol 87(5):377–390PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Depelsenaire ACI, Kendall MAF, Young PR, Muller DA (2017) Introduction to vaccines and vaccination. In: Skwarczynski M, Toth I (eds) Micro and nanotechnology in vaccine development. Elsevier, AmsterdamGoogle Scholar
  116. 116.
    Barrett AD (2015) 9 licensed vaccines for humans. Vaccinology: an essential guide. 152–180Google Scholar
  117. 117.
    Pattison DI, Davies MJ (2001) Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem Res Toxicol 14:1453–1464.  https://doi.org/10.1021/tx0155451CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Hakim H, Alam MS, Sangsriratanakul N, Nakajima K, Kitazawa M, Ota M, Toyofuku C, Yamada M, Thammakarn C, Shoham D, Takehara K (2016) Inactivation of bacteria on surfaces by sprayed slightly acidic hypochlorous acid water: in vitro experiments. J Vet Med Sci 78(7):1123–1128.  https://doi.org/10.1292/jvms.16-0075CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Pattison DI, Hawkins CL, Davies MJ (2003) Hypochlorous acid-mediated oxidation of lipid components and antioxidants present in low-density lipoproteins: absolute rate constants, product analysis, and computational modeling. Chem Res Toxicol 16(4):439–449PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G (2013) A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19(17):4801–4815PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Seo HS (2015) Application of radiation technology in vaccines development. Clin Exp Vaccine Res 4(2):145–158PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    da Silva Aquino KA (2012) Sterilization by gamma irradiation. In Gamma radiation. IntechOpen.  https://doi.org/10.5772/34901
  123. 123.
    Babb R, Chen A, Hirst TR et al (2016) Intranasal vaccination with γ-irradiated Streptococcus pneumoniae whole-cell vaccine provides serotype-independent protection mediated by B-cells and innate IL-17 responses. Clin Sci 130(9):697–710PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Parham P (2014) The immune system. Garland Science, New YorkCrossRefGoogle Scholar
  125. 125.
    Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11(4s):S45PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Authors and Affiliations

  1. 1.Department of Biotechnology, University Institute of Engineering and TechnologyMaharshi Dayanand University RohtakRohtakIndia
  2. 2.Enzyme Technology and Protein Bioinformatics Laboratory, Department of MicrobiologyMaharshi Dayanand University RohtakRohtakIndia
  3. 3.Department of BiotechnologyCentral University of HaryanaMahendergarhIndia
  4. 4.Department of Clinical ImmunologyAllergology and Microbiology, Karaganda Medical UniversityKaragandaKazakhstan

Personalised recommendations

Cite protocol

Buy options